STENOCARE A/S: Publication of investment brochure
STENOCARE A/S
NASDAQ FIRST NORTH GROWTH MARKET, DENMARK
TICKER: STENO
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE.
STENOCARE A/S (“Stenocare” or the “Company”) announced the exercise price of 3.16 DKK per share in relation to the TO2 warrant exercise. The exercise period commenced 10 June 2024 and runs until 21 June 2024. The Company has published an investment brochure with information about Stenocare and the planned activities.
The summary
Summarized terms for the warrants of series TO2:
- Exercise price: 3.16 DKK per share – ticker: [STENO TO 2] / ISIN DK0062493615
- Exercise period: 10 June 2024 – 21 June 2024 (both days included)
- Last day of trading warrants of series TO2: 19 June 2024
- Issue volume: 1,712,999 warrants of series TO2
- Dilution: Up to 8.5 percent
The investment brochure
To inform existing shareholders of Stenocare and other investors and stakeholders about the exercise of TO2 warrants, an investment brochure has been prepared. This brochure contains details about the Company, its business, products and strategy. It is attached to this announcement and is also available on the website of Stenocare https://stenocare.com/share-issue-to2-2024/
- Link to English brochure: https://stenocare.com/wp-content/uploads/2024/06/STENOCARE-TO2-Warrant-exercise-ENG.pdf
- Link to Danish brochure: https://stenocare.com/wp-content/uploads/2024/06/STENOCARE-TO2-Warrant-udnyttelse-DK_.pdf
- Link to Swedish brochure: https://stenocare.com/wp-content/uploads/2024/06/STENOCARE-TO2-Warrant-nyttjande-SE_.pdf
Advisors
Stenocare mandated Gemstone Capital as financial advisor and Danske Bank as settlement agent. Keswick Global AG is Stenocare’s certified advisor.
For additional information regarding STENOCARE, please contact:
Thomas Skovlund Schnegelsberg, CEO Phone: +45 31770060 E-mail: presse@stenocare.com
STENOCARE’s Certified Adviser is Keswick Global AG / Phone: +43 1 740 408045 / E-mail: info@keswickglobal.com
Financial Adviser is Gemstone Capital A/S, Sadjad Hassani, Associate Director, Phone: +45 33220700 info@gemstonecapital.com
About STENOCARE A/S
Stenocare was founded in 2017 with the purpose of supplying prescription-based medical cannabis to patients in Denmark and internationally. The company was first to receive the Danish Medicines Agency's permission to import, distribute as well as cultivate and produce medical cannabis. Stenocare sources its products from a number of carefully selected international high-quality suppliers and operates a unique, indoor state-of-the-art cultivation facility in Denmark.